New Mayo Venture Partner (MVP) program announced to accelerate innovation - Middle East Business News and Information
Dubai, United Arab Emirates; June, 2025 — Mayo Clinic's Business Development team, consistently recognized as one of the top commercialization operations among academic medical centers, is expanding its capabilities through a new initiative: the Mayo Venture Partner (MVP) program. In response to the dynamic and evolving healthcare landscape, Mayo Clinic is enlisting industry veterans to create groundbreaking technologies, co-invest in aligned companies and build new ventures from the ground up.
The MVP program brings together seasoned entrepreneurs, investors and executives who will leverage their expertise with Mayo Clinic's world-class research and clinical expertise. These leaders will play a pivotal role in identifying high-potential opportunities across Mayo Clinic's research and clinical practices, forming new companies and accelerating innovations that advance patient care.
The inaugural MVPs are: Amy DuRoss — Healthcare innovation leader with deep expertise in policy, commercialization and diagnostics.
Audrey Greenberg — Company builder, executive leader and expert in launching and scaling ventures across life sciences, healthcare and other industries.
Brian Poger — Serial entrepreneur and venture strategist with a track record in digital health and healthcare services.
Working in close partnership with the Mayo Clinic Business Development team, the MVPs will help forge strategic collaborations and deliver real-world impact, underscoring Mayo Clinic's enduring commitment to transforming healthcare.
To date, the Business Development team has returned more than $1.2B in revenue to Mayo Clinic to support its clinical practice, education and research. Additionally, the team has helped create more than 180 companies, licensed 4,848 Mayo Clinic-created technologies through 2,913 agreements, and issued 4,159 patents.
This program and these efforts align with Mayo Clinic's vision to transform healthcare by: Accelerating innovation — Turning cutting-edge research, data and other resources into real-world solutions for patients.
Enhancing patient care — Bringing new treatments and technologies to patients that offer cures and the ability to connect with the healthcare system in ways that increase access and decrease costs.
Building strategic partnerships — Leveraging external expertise and resources to amplify impact.
Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting opportunity for investors, CEOs and innovators to collaborate with Mayo Clinic and be part of a future that prioritizes patient-centric, transformative healthcare solutions.
To learn more, visit the Mayo Clinic Business Development website and subscribe to its e-newsletter and follow the Mayo Clinic Ventures LinkedIn page.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 days ago
- Mid East Info
Mayo Clinic uncovers brain cell changes that could explain Tourette syndrome - Middle East Business News and Information
Dubai, United Arab Emirates; June , 2025 — A new Mayo Clinic study finds that people with Tourette syndrome have about half as many of a specific type of brain cell that helps calm overactive movement signals as people without the condition. This deficit may be a key reason why their motor signals go unchecked, leading to the involuntary tics that define the disorder. The study, published in Biological Psychiatry, is the first to analyze individual brain cells from people with Tourette disorder. The findings also shed light on how different types of brain cells may interact in ways that contribute to the syndrome's symptoms. 'This research may help lay the foundation for a new generation of treatments,' says Alexej Abyzov, Ph.D., a genomic scientist in Mayo Clinic's Center for Individualized Medicine and a co-author of the study. 'If we can understand how these brain cells are altered and how they interact, we may be able to intervene earlier and more precisely.' Tourette disorder is a neurodevelopmental condition that typically begins in childhood. It causes repeated, involuntary movements and vocalizations such as eye blinking, throat clearing or facial grimacing. While genetic studies have identified some risk genes, the biological mechanisms behind the condition have remained unclear. To better understand what's happening in the brain with Tourette syndrome, Dr. Abyzov and his team analyzed more than 43,000 individual cells from postmortem brain tissue of people with and without the condition. They focused on the basal ganglia, a region of the brain that helps control movement and behavior. In each cell, they looked at how genes were working. They also analyzed how changes in the brain's gene-control systems might trigger stress and inflammation. First, they found in people with Tourette syndrome a 50% reduction in interneurons, which are brain cells that help calm excess signals in the brain's movement circuits. They also observed stress responses in two other brain cell types. Medium spiny neurons, which make up most of the cells in basal ganglia and help send movement signals, showed reduced energy production. Microglia, the brain's immune cells, showed inflammation. The two responses were closely linked, suggesting the cells may be interacting in Tourette disorder. 'We're seeing different types of brain cells reacting to stress and possibly communicating with each other in ways that could be driving symptoms,' says Yifan Wang, Ph.D., co-author of the study. The study also provides evidence that the underlying cause of brain cell changes in Tourette disorder may be linked to parts of DNA that control when genes turn on and off. 'Tourette patients seem to have the same functional genes as everyone else but the coordination between them is broken,' Dr. Abyzov says. Next, the researchers plan to study how these brain changes develop over time and look for genetic factors that may help explain the disorder. The study was conducted in collaboration with the lab of Flora M. Vaccarino, M.D., at Yale University. For a complete list of authors, disclosures and funding, review the study.
Al-Ahram Weekly
7 days ago
- Al-Ahram Weekly
French scientists discover new blood type in Guadeloupe woman - Health - Life & Style
French scientists have identified a new blood type, dubbed "Gwada negative", belonging to a French woman from the Caribbean island of Guadeloupe. The woman is the only known carrier of what is now the world's 48th identified blood group system. A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems. Correctly identifying patients' blood types is a crucial step in allowing them to receive potentially life-saving transfusions from compatible blood groups Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world", said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s, where blood type is identified by the presence or absence of specific antigens. Thanks to DNA sequencing, the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said. Follow us on: Facebook Instagram Whatsapp Short link:
Mid East Info
10-06-2025
- Mid East Info
New Mayo Venture Partner (MVP) program announced to accelerate innovation - Middle East Business News and Information
Dubai, United Arab Emirates; June, 2025 — Mayo Clinic's Business Development team, consistently recognized as one of the top commercialization operations among academic medical centers, is expanding its capabilities through a new initiative: the Mayo Venture Partner (MVP) program. In response to the dynamic and evolving healthcare landscape, Mayo Clinic is enlisting industry veterans to create groundbreaking technologies, co-invest in aligned companies and build new ventures from the ground up. The MVP program brings together seasoned entrepreneurs, investors and executives who will leverage their expertise with Mayo Clinic's world-class research and clinical expertise. These leaders will play a pivotal role in identifying high-potential opportunities across Mayo Clinic's research and clinical practices, forming new companies and accelerating innovations that advance patient care. The inaugural MVPs are: Amy DuRoss — Healthcare innovation leader with deep expertise in policy, commercialization and diagnostics. Audrey Greenberg — Company builder, executive leader and expert in launching and scaling ventures across life sciences, healthcare and other industries. Brian Poger — Serial entrepreneur and venture strategist with a track record in digital health and healthcare services. Working in close partnership with the Mayo Clinic Business Development team, the MVPs will help forge strategic collaborations and deliver real-world impact, underscoring Mayo Clinic's enduring commitment to transforming healthcare. To date, the Business Development team has returned more than $1.2B in revenue to Mayo Clinic to support its clinical practice, education and research. Additionally, the team has helped create more than 180 companies, licensed 4,848 Mayo Clinic-created technologies through 2,913 agreements, and issued 4,159 patents. This program and these efforts align with Mayo Clinic's vision to transform healthcare by: Accelerating innovation — Turning cutting-edge research, data and other resources into real-world solutions for patients. Enhancing patient care — Bringing new treatments and technologies to patients that offer cures and the ability to connect with the healthcare system in ways that increase access and decrease costs. Building strategic partnerships — Leveraging external expertise and resources to amplify impact. Mayo Clinic is dedicated to driving progress and expanding its impact through innovation. This initiative is an exciting opportunity for investors, CEOs and innovators to collaborate with Mayo Clinic and be part of a future that prioritizes patient-centric, transformative healthcare solutions. To learn more, visit the Mayo Clinic Business Development website and subscribe to its e-newsletter and follow the Mayo Clinic Ventures LinkedIn page.
